[PDF][PDF] Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
AF Cashen, GJ Schiller, MR O'Donnell… - Journal of Clinical …, 2010 - Citeseer
AF Cashen, GJ Schiller, MR O'Donnell, JF DiPersio
Journal of Clinical Oncology, 2010•CiteseerPurpose Older patients with acute myeloid leukemia (AML) have limited treatment options
because of the lack of effectiveness and the toxicity of available therapies. We investigated
the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older
patients with AML.
because of the lack of effectiveness and the toxicity of available therapies. We investigated
the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older
patients with AML.
Purpose
Older patients with acute myeloid leukemia (AML) have limited treatment options because of the lack of effectiveness and the toxicity of available therapies. We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML.
Citeseer
